These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15220700)

  • 1. Lack of recurrence of hyperlactatemia in HIV-infected patients switched from stavudine to abacavir or zidovudine.
    Lonergan JT; McComsey GA; Fisher RL; Shalit P; File TM; Ward DJ; Williams VC; Hessenthaler SM; Lindsey L; Hernandez JE;
    J Acquir Immune Defic Syndr; 2004 Aug; 36(4):935-42. PubMed ID: 15220700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
    JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtle decreases in stavudine phenotypic susceptibility predict poor virologic response to stavudine monotherapy in zidovudine-experienced patients.
    Shulman NS; Hughes MD; Winters MA; Shafer RW; Zolopa AR; Hellmann NS; Bates M; Whitcomb JM; Katzenstein DA
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):121-7. PubMed ID: 12394789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
    Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
    Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
    Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
    Lonergan JT; Barber RE; Mathews WC
    AIDS; 2003 Nov; 17(17):2495-9. PubMed ID: 14600521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
    John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
    J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA; de Jong JJ; Jan Weverling G; van Benthem BH; Maas J; Keet IP; Jurriaans S; Roos MT; Vandermeulen K; de Wolf F; Lange JM
    AIDS; 1998 Aug; 12(12):1513-9. PubMed ID: 9727573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
    McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
    Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short communication: benefits in the lipid profile after substitution of abacavir for Stavudine: a 48-week prospective study.
    García-Benayas T; Blanco F; Alcolea A; Cruz JJ; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1289-92. PubMed ID: 15650420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo antagonism with zidovudine plus stavudine combination therapy.
    Havlir DV; Tierney C; Friedland GH; Pollard RB; Smeaton L; Sommadossi JP; Fox L; Kessler H; Fife KH; Richman DD
    J Infect Dis; 2000 Jul; 182(1):321-5. PubMed ID: 10882616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
    McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
    AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy.
    Shulman NS; Machekano RA; Shafer RW; Winters MA; Zolopa AR; Liou SH; Hughes M; Katzenstein DA;
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):377-80. PubMed ID: 11468426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
    Ungsedhapand C; Srasuebkul P; Cardiello P; Ruxrungtham K; Ratanasuwan W; Kroon ED; Tongtalung M; Juengprasert N; Ubolyam S; Siangphoe U; Emery S; Lange JM; Cooper DA; Phanuphak P;
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):693-701. PubMed ID: 15167288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.
    Kuritzkes DR; Marschner I; Johnson VA; Bassett R; Eron JJ; Fischl MA; Murphy RL; Fife K; Maenza J; Rosandich ME; Bell D; Wood K; Sommadossi JP; Pettinelli C
    AIDS; 1999 Apr; 13(6):685-94. PubMed ID: 10397563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
    Shlay JC; Sharma S; Peng G; Gibert CL; Grunfeld C
    J Acquir Immune Defic Syndr; 2008 May; 48(1):53-62. PubMed ID: 18491421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.